Wire · operational-macro
FDA Grants RMAT Designation to iSCIB1+ in Advanced Melanoma
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 21 November 2026 · Fusion42 review
The FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to iSCIB1+ for the treatment of advanced melanoma, indicating a regulatory fast-track to potentially accelerate its development and review.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
The FDA's RMAT designation creates a faster path through approval hurdles for therapies like iSCIB1+. You in biotech should prepare to engage earlier in clinical discussions and investor relations to capitalise on this regulatory boost.
◆ Coverage
1 source · 21 Nov 2026
◆ Related on Wire
◆ Topics